Industries We Serve / Hospitals & Health Systems / Transplant Programs
Transplant Program & Centers of Excellence AdvisoryEvery Organ. Every Phase. Every Dollar Accounted For.
Centers of Excellence contracting, organ acquisition economics and program strategy for transplant hospitals and the health systems behind them.
Scroll to explore- 49,064U.S. organ transplants in 2025UNOS / OPTN, Jan 2026
- 109,817Candidates on the national waiting listHRSA / OPTN, Jul 2026
- 250U.S. transplant hospitalsOPTN membership, Nov 2026
- 95Kidney transplant hospitals in CMS's IOTA model, year 2CMS, Jul 2026
The Transplant Landscape
Each Organ Is Its Own Business
Volume, waiting lists and the charge profile of each phase of care differ sharply by organ. Select one.
Kidney: Billed Charges by Phase of Care
Billed charges by phase: 30 days before, organ procurement, transplant admission, physician services, 180 days after discharge, outpatient drugs.
Transplants and waiting list: HRSA organdonor.gov, OPTN data as of 30 Jul 2026 (2025 calendar year; waiting list is a snapshot of candidates). Charges: Milliman, "2025 U.S. Organ and Tissue Transplants" (Feb 2025)—estimated average billed charges, not payments, from 30 days before admission to 180 days after discharge. Lung charges shown for double lung.
Transplant Economics
Where Transplant Margins Are Won and Lost
Four mechanics decide whether a program funds itself. Select one.
One price, many phases
COE contracts commonly bundle evaluation, the transplant admission and a defined follow-up period into phase-based case rates. Each phase has to be priced against its own cost.
Paid on cost, outside the DRG
Medicare reimburses organ acquisition costs at reasonable cost through the cost report, using the share of usable organs that went to Medicare patients.
42 CFR 412.2(e)(4), 412.113(d); 42 CFR 413 Subpart L
A few cases set the year
A handful of complicated admissions can erase a year of case-rate margin. Outlier thresholds and stop-loss terms decide who carries that risk.
The relationship doesn't end at discharge
Follow-up visits, labs and immunosuppressants continue for years. Medicare Part B-ID has covered immunosuppressants for eligible kidney recipients since 2023.
CMS, Part B Immunosuppressive Drug benefit (effective 1 Jan 2023)
Price the Contract Before You Sign It
Model phase-level margin and outlier exposure against your own cost.
How We Help
Five Ways to Strengthen a Transplant Program

Centers of Excellence Contracting
Our founding discipline, applied to transplant: win and keep COE designations on terms that cover cost.
- Phase-of-care case rate design and pricing
- Outlier, stop-loss and carve-out terms
- COE application and renewal strategy
- Network and transplant-network negotiations

Organ Acquisition Cost
Organ acquisition is reimbursed on cost—so the cost center, statistics and usable-organ counts have to hold up.
- OAC cost center and allocation review
- Medicare usable-organ ratio support
- Interim payment and settlement analysis
- OPO and lab agreement economics

Program Economics & Performance
A P&L for each organ program, from referral to long-term follow-up—built on phase-level cost, not averages.
- Organ-level contribution and margin
- Phase-of-care costing
- Underpayment recovery on transplant claims
- Capacity, staffing and OR utilization

Quality, Regulation & IOTA
The outcomes payers and regulators see—SRTR, Medicare approval and CMS's kidney model—translated into strategy.
- SRTR program-report interpretation
- CMS transplant program requirements
- IOTA model performance and payment
- OPTN policy change readiness

Growth & Referral Networks
Grow volume where it is sustainable: referral relationships, living donation and new organ programs.
- Referring nephrology and hepatology networks
- Living donor program development
- New organ program feasibility
- Surgeon and physician alignment
Transplant Advisory Studio
Model the Program Before the Payer Does
Three working models with illustrative defaults. Everything recalculates in your browser.
Rate vs. Cost by Phase, Typical Case ($K)
Case rate and cost by phase of care.
Navy: case rate · Gray: cost. Expected margin = cases × [(1 − outlier share) × typical margin + outlier share × outlier margin]. Outlier admission cost = admission cost × multiple; stop-loss pays the stated % of cost above the threshold. Excludes organ acquisition (often handled separately), professional fees and drugs unless built into the phase rates. Contract structures vary; illustrative only.
Settlement Sensitivity ($M)
| Medicare usable organs | Cost −5% | As entered | Cost +5% |
|---|---|---|---|
| As entered | — | — | — |
Where the Cost Goes ($M)
Organ acquisition cost split between Medicare and other payers.
Medicare share = supportable OAC × (Medicare usable organs ÷ total usable organs). Settlement = Medicare share − interim payments (positive = receivable). Before any applicable payment adjustments. Organ acquisition costs are excluded from the MS-DRG and paid at reasonable cost (42 CFR 412.2(e)(4), 412.113(d); 413 Subpart L).
Contribution and Allocated Fixed Cost by Organ ($M)
Contribution and allocated fixed cost by organ program.
Navy/magenta: contribution (volume × (revenue − direct cost)) · Brass: fixed cost allocated by volume share. Allocation by volume is a simplification; real programs allocate by resource use. Excludes downstream and referral revenue.
| Organ | Margin / case | Break-even volume | After allocation |
|---|---|---|---|
| Kidney | — | — | — |
Your contracts, cost report and claims tell the real story.
Request a Transplant Program AssessmentPolicy Watch · 16 November 2026
The Rules Reshaping Transplant Programs
IOTA Kidney Model
Up to $15,000 upside or $2,000 downside per Medicare kidney transplant, by performance score. Six years from July 2025.
42 CFR 512.430; CMSSRTR Program Reports
Released each January and July; tiers now shown as dial icons since March 2026.
SRTROPO Recertification
Recertification decisions under CMS's OPO outcome tiers come at the end of the 2022–2026 cycle; final rule CMS-3409-F issued Oct 2026.
CMSPart B-ID Coverage
Immunosuppressive drug coverage for eligible kidney recipients after ESRD Medicare ends.
CMSMedicare vs. Commercial COE Economics
The same transplant is paid two very different ways. Strategy has to work for both.
| Traditional Medicare | Commercial COE Contract | |
|---|---|---|
| Transplant admission | MS-DRG payment | Negotiated phase-based case rate |
| Organ acquisition | Reasonable cost via cost report, outside the DRG | Negotiated: included or separately paid |
| Quality gate | CMS program approval requirements | Payer COE criteria: volume, SRTR outcomes, cost |
Sources: 42 CFR 512.430 (as amended 1 Jun 2026) and CMS IOTA fact sheets; SRTR (Jul 2026); CMS-3409-F (Oct 2026); CMS Part B-ID; 42 CFR 412.2(e)(4), 412.113(d), 482.80. Commercial terms vary by contract.
Our Approach
From Contract Review to Centers of Excellence
A 90-day assessment, then a 12- to 18-month contracting and performance cycle. Select a phase.
Contract inventory, SRTR position, COE designations held and missing.
Phase-of-care cost by organ, outlier history and OAC review.
Case-rate pricing, stop-loss terms and COE application plan.
Payer and network negotiations, applications and renewals.
Contract performance tracking, recovery and SRTR monitoring.
Illustrative 18-month workplan.
Illustrative workplan. Timing and outcomes depend on each program.
COE Readiness Check
How Ready Is Your Program for Centers of Excellence?
Twelve questions with sample answers filled in—change them to yours. Scored in your browser; nothing is stored or sent.
Readiness score by domain.
Your Readiness Summary
Answer the questions to build your summary.
A self-assessment for discussion, not a payer's criteria or a prediction of designation. Scoring: Yes 2, Partly 1, No or not sure 0, equally weighted.
Fulcrum Intelligence
Perspectives on Payer Strategy
The State of Commercial Payer Contracting in 2026
2026 Payer AnalyticsWhy Provider Organizations Are Investing in Managed Care Analytics
2026 CMS & Payment PolicyThe CY2027 Medicare Final Rules: What Moved, and Who Pays
Nov 2026Questions, Answered
What Is a Transplant Center of Excellence?
A Center of Excellence is a transplant program a payer or transplant network has designated for its members, usually based on outcomes, volume and cost. Designation can steer patients to the program, typically under negotiated case rates.
How Are Transplant Case Rates Structured?
Commercial transplant contracts commonly set rates by phase of care—evaluation, pre-transplant, the transplant admission and a defined follow-up period—with outlier or stop-loss terms for unusually expensive cases. Structures vary by payer and contract.
How Does Medicare Pay for Organ Acquisition?
Medicare excludes organ acquisition costs from the MS-DRG and pays them at reasonable cost through the hospital's cost report, based on the share of usable organs transplanted into Medicare beneficiaries.
What Do SRTR Program-Specific Reports Measure?
SRTR reports transplant rates, waitlist outcomes, offer acceptance and graft and patient survival for each program, with a five-tier assessment. Reports are released each January and July.
What Is the IOTA Model?
CMS's Increasing Organ Transplant Access Model is a mandatory, six-year kidney transplant model that began in July 2025. Participating hospitals can earn up to $15,000 or owe up to $2,000 per Medicare kidney transplant, based on performance.
How Can a Transplant Program Improve Its Margin?
Margin usually improves through case rates priced to phase-level cost, defined outlier protection, accurate organ acquisition cost reporting, recovered underpayments and volume growth through referral networks and living donation.
Build a Transplant Program That Funds Its Mission
Centers of Excellence contracts, organ acquisition economics and program strategy—from one senior team.
